We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Ending Pay-For-Delay Deals Could Raise over $5 Billion
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Ending Pay-For-Delay Deals Could Raise over $5 Billion
BusinessNewsPolicy & Law

Ending Pay-For-Delay Deals Could Raise over $5 Billion

gooznews
gooznews
Share
3 Min Read
SHARE

The deficit reduction “super committee” charged with coming up with $1.2 trillion in budget reductions over the next decade shouldn’t let this one pass. The Congressional Budget Office today estimated that ending drug industry “pay for delay” deals with generic manufacturers will save the federal government over $5 billion over the next decade.

The deficit reduction “super committee” charged with coming up with $1.2 trillion in budget reductions over the next decade shouldn’t let this one pass. The Congressional Budget Office today estimated that ending drug industry “pay for delay” deals with generic manufacturers will save the federal government over $5 billion over the next decade.

The “Preserve Access to Affordable Generics Act,” sponsored Sen. Herb Kohl, D-Wis., with eight co-sponsors, including two Republicans, requires that any deal between two companies that delays production of a generic drug after a patent has expired must show that the deal is “pro competitive,” which would effectively ban the practice. The Federal Trade Commission issued a report a year ago that found 66 of these deals reached over the past half decade were costing consumers about $3.5 billion a year.

Pharmaceutical industry lobbyists succeeded in stripping an earlier version of Kohl’s bill from the health care reform law. At the time, CBO had estimated it would save the government about $2.8 billion. Now, with Lipitor coming off patent and several more blockbusters to follow, the stakes are considerably higher. The latest CBO report estimates the legislation will save Medicare and Medicaid $4 billion by lowering drug prices between 2012 and 2021. Over the same time period, the government would generate about $800 million in additional taxes and reduce administrative expenses by about $400 million.

More Read

Can “Portfolio Theory” Be Applied to NIH Funding Decisions?
Want the Young and Invincible to Buy Into Obamacare? Answer These 3 Questions
Try These Powerful Ayurvedic Tips To Stay Healthy
5 Solutions to Hospital Productivity Woes
Beyond the Buzz: A Healthcare Guide to Maintaining Professionalism on Facebook

This bill’s a no brainer. If the Super Committee recommends further cuts to Medicare and Medicaid without ending pay for delay deals or requiring drug and biotech companies to offer Medicare the same low prices they offer Medicaid, consumers and patients will know who won the behind-the-scenes lobbying battle now raging on Capitol Hill.

TAGGED:pay for delaypharmaceutical companies
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

The Nervous System Reset Guide: Simple Ways To Manage Stress -- AI-generated illustration
The Nervous System Reset Guide: Simple Ways To Manage Stress
Infographics Mental Health
November 14, 2026
Flat editorial illustration: A single digital quality-management platform connects document control, electronic approval, audit r
6 Best QMS Software Platforms for ISO 13485 and FDA Part 820 (QMSR)
Global Healthcare Policy & Law
November 12, 2026
Flat editorial illustration: Healthcare editorial illustration about accurate patient intake connecting registration, clinical re
The Role of Patient Data Accuracy in Healthcare Operations
Global Healthcare Policy & Law
November 11, 2026
Flat editorial illustration: Healthcare ethics-and-law training, shown through a coached clinical role-play where structured disc
Medical Ethics and the Law: The Training Behind Professionals Who Resolve Healthcare Disputes
Uncategorized
November 6, 2026

You Might also Like

Quality of Life Adjustments Don’t Matter for Cancer Treatment Cost Effectiveness

March 4, 2011
Congressman James Lankford
BusinessHealth ReformPolicy & Law

Lankford Introduces Legislation Giving Congressional Authority to Interstate Health Care Compact

March 13, 2014

Changing Behavior to Conquer Obesity

September 23, 2012

Does Caffeine Reduce Depression?

December 13, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?